A House committee voted last week to advance legislation that would ban contracting with five key Chinese biotech firms and set in motion a reordering of how U.S. pharmaceuticals are developed and manufactured.
The House Committee on Oversight and Accountability voted overwhelmingly to approve the Biosecure Act. The. Senate Homeland Security and Governmental Affairs committee already approved similar legislation in March. The bipartisan legislation would end U.S. contracting with Chinese firms such as WuXi AppTec and others deemed a threat to national security by 2032.
"This bill is a necessary step toward protecting America's sensitive health-care data from the Chinese Communist Party before these companies become more embedded in the U.S. economy," Committee Chair Rep. James Comer, R-Ky., said.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
